Medical Publisher in Delhi, India - IP Innovative Publication Pvt Limited, Medical Journals Publication, Open Access Journals, Print Journals,Indian Journals, Surgery, Microbiology, Anaesthesia, Anatomy Biochemistry Books and Journals, Skills for Employability,Best Journal Publishers-IP Innovative Publication Pvt Limit

Carbapenemase detection amongst Acinetobacter baumannii and Klebsiella pnuemoniae - IJMMTD- Print ISSN No: - 2581-4753 Online ISSN No:- 2581-4761 Article DOI No:- 10.18231/j.ijmmtd.2025.008, IP International Journal of Medical Microbiology and Tropical Diseases-IP Int J Med Microbiol Trop Dis

Multidrug-resistant (MDR) Acinetobacter is an important pathogen which has a number of virulence characters that enable them to render resistance to antibiotics thus complicating the treatment options, thereby forcing clinicians to rely on last resort antibiotic such as colistin. However, resistance to colistin has also been reported, further increasing the challenge. To detect the rate of colistin resistance and carbapenemase production among MDR Acinetobacter baumannii isolates from a tertiary care hospital in South India. This is a prospective study conducted over a period of 15 months from August 2023 to October 2024 and included 110 isolates of MDR Acinetobacter baumannii. All the isolates were subjected to colistin resistance detection using microbroth dilution method and carbapenemase production using mCIM and eCIM methods. Of the 110 isolates of MDR A. baumannii, 19 (17.27%) showed colistin resistance. The mCIM and eCIM tests showed 70 (63.63%) serine carbapenemase producers and 61 (55.45%) metallo beta-lactamase producers. This study underscores the concerning prevalence of resistance determinants among MDR A. baumannii, providing clinicians and infection control specialists with essential data to guide the formulation of effective empirical treatment strategies and infection control measures.

Gram-negative bacterial infections that are resistant to carbapenems are a serious clinical problem. The only effective drugs against them are still tigecycline and colistin. In fact, polymyxin E, also known as colistin, has been regarded as a "last resort" antibiotic. But in recent years, colistin resistance has increased globally, significantly reducing treatment options and highlighting the significance of accurate colistin testing methods to support appropriate therapeutic decision-making. There is no requirement to cite reference in the So it is suggested to rephrase the sentence. The primary goal of the study is to compare the effectiveness of E-test and Vitek 2 for colistin sensitivity testing to the conventional microbroth dilution method using 120 clinical isolates of and that are resistant to carbapenem over the course of a year, isolated from January to December 2019. In comparison to Vitek-2, the results indicated that brothmicro dilution and E-test produced the narrowest range of colistin MICs. After comparing the E-test's errors and overall agreement with BMD, 100% of the Essential Agreement, 94.27% of the Categorical Agreement, and 5.72% of the Very Major Errors with no Major Errors were found. Comparing Vitek-2 with BMD, similar results were found: 1.66% MEs, 98.32% CAs, 80.99% EAs, and no VMEs. As a result, it was determined that, in contrast to Vitek-2, MBD and E-test had distinct MICs, making them appropriate for determining colistin MIC. It will take more research on automated systems to standardize colistin susceptibility testing procedures, particularly for and .

Multidrug resistant (MDR) Acinetobacter is an important pathogen which has a number of virulence characteristics that enable them to render resistance to antibiotics thus complicates the treatment options, thereby forcing clinicians to rely on last resort antibiotic such as colistin. However, resistance to colistin has also been reported, further increasing the challenge. To detect the virulence attributes, colistin resistance and carbapenemase production in MDR Acinetobacter baumannii from a tertiary care hospital in South India. This is a prospective study conducted over a period of 15 months from August 2023 to October 2024 with 110 isolates of MDR Acinetobacter baumannii. All the isolates were subjected to colistin resistance detection using microbroth dilution method, carbapenemase detection using mCIM and eCIM methods, virulence detection like biofilm production by tissue culture plate method, haemolytic activity on blood agar, proteolytic activity on milk agar and siderophore production on Chrome Azurol S agar. Of the 110 isolates of MDR A. baumannii, 19 (17.27%) showed colistin resistance, 89 (80.90%) showed biofilm production, 35 (31.81%) showed haemolysis, 60 (54.54%) showed proteolysis and 49 (44.54%) showed siderophore production. The serine carbapenemase from mCIM and metallo beta-lactamase producers from eCIM tests were 61 (55.45%) serine carbapenemase and 70 (63.63%) respectively. This study underscores the concerning prevalence of virulence and resistance determinants among MDR A. baumannii, providing clinicians and infection control specialists with essential data to guide the formulation of effective empirical treatment strategies and infection control measures.